{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T13:10:42Z","timestamp":1793970642168,"version":"4.8.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T00:00:00Z","timestamp":1766707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Population ageing is posing significant challenges for healthcare systems and societies worldwide. Neurodegenerative diseases, including Alzheimer\u2019s disease and Parkinson\u2019s disease, are among the leading contributors to disability, dependence, and healthcare costs in ageing societies. Prevention offers the most sustainable approach to reducing the burden of neurodegenerative diseases. While Alzheimer\u2019s disease prevention is already advancing through biomarker-based early detection, identification of modifiable risk factors, and multi-domain interventions, efforts are now turning towards Parkinson\u2019s disease, the fastest growing neurodegenerative disorder. Using deeply phenotyped cohorts of patients with Parkinson\u2019s disease and people with prodromal stages of neurodegenerative diseases, novel biomarkers have enabled biological classification for improved diagnosis of Parkinson\u2019s disease, including early cognitive impairments. The expanding knowledge of Parkinson\u2019s disease risk factors is now being translated into primary and secondary prevention concepts within integrated care settings to effectively address the burden of neurodegenerative diseases for the people affected. Integrating biomarker-based risk stratification with scalable life-style based programmes offers a realistic pathway toward precision prevention in Parkinson\u2019s disease.<\/jats:p>","DOI":"10.1007\/s00702-025-03090-z","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T08:51:50Z","timestamp":1766739110000},"page":"265-277","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Precision prevention for neurodegenerative diseases: lessons learnt from Alzheimer\u2019s disease translated into perspectives for Parkinson\u2019s disease"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5018-9903","authenticated-orcid":false,"given":"Sibylle","family":"B\u00e9chet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3112-9918","authenticated-orcid":false,"given":"Morgan","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8016-060X","authenticated-orcid":false,"given":"Esther","family":"Ademola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4694-3923","authenticated-orcid":false,"given":"Jo\u00eblle V.","family":"Fritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4258-6241","authenticated-orcid":false,"given":"Rejko","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,26]]},"reference":[{"issue":"13","key":"3090_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1212\/01.wnl.0000338632.00552.cb","volume":"72","author":"D Aarsland","year":"2009","unstructured":"Aarsland D, Bronnick K, Larsen JP, Tysnes OB, Alves G, Norwegian ParkWest Study, G (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72(13):1121\u20131126. https:\/\/doi.org\/10.1212\/01.wnl.0000338632.00552.cb","journal-title":"Neurology"},{"issue":"1","key":"3090_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00280-3","volume":"7","author":"D Aarsland","year":"2021","unstructured":"Aarsland D, Batzu L, Halliday GM, Geurtsen GJ, Ballard C, Ray Chaudhuri K, Weintraub D (2021) Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers 7(1):47. https:\/\/doi.org\/10.1038\/s41572-021-00280-3","journal-title":"Nat Rev Dis Primers"},{"key":"3090_CR41","unstructured":"Alzheimer Centrum Limburg (n.d.) We are the medicine ourselves\u2019 [Dutch: \u2018We zijn zelf het medicijn\u2019] public health campaign. Retrieved 30 October 2025 from https:\/\/wezijnzelfhetmedicijn.nl"},{"issue":"1","key":"3090_CR3","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ana.26949","volume":"96","author":"G Arena","year":"2024","unstructured":"Arena G, Landoulsi Z, Grossmann D, Payne T, Vitali A, Delcambre S, Baron A, Antony P, Boussaad I, Bobbili DR, Sreelatha AAK, Pavelka L, J Diederich N, Klein C, Seibler P, Glaab E, Foltynie T, Bandmann O, Sharma M, Kr\u00fcger R, NCER\u2010PD and COURAGE\u2010PD Consortia (2024) Polygenic risk scores validated in patient-derived cells stratify for mitochondrial subtypes of Parkinson\u2019s disease. Ann Neurol 96(1):133\u2013149. https:\/\/doi.org\/10.1002\/ana.26949","journal-title":"Ann Neurol"},{"issue":"1","key":"3090_CR4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/mds.27902","volume":"35","author":"C Baiano","year":"2020","unstructured":"Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment in Parkinson\u2019s disease: a meta-analysis. Mov Disord 35(1):45\u201354. https:\/\/doi.org\/10.1002\/mds.27902","journal-title":"Mov Disord"},{"issue":"8","key":"3090_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/jama.2025.12923","volume":"334","author":"LD Baker","year":"2025","unstructured":"Baker LD, Espeland MA, Whitmer RA, Snyder HM, Leng X, Lovato L, Papp KV, Yu M, Kivipelto M, Alexander AS, Antkowiak S, Cleveland M, Day C, Elbein R, Tomaszewski Farias S, Felton D, Garcia KR, Gitelman DR, Graef S, Carrillo MC (2025) Structured vs self-guided multidomain lifestyle interventions for global cognitive function: the US POINTER randomized clinical trial. JAMA 334(8):681\u2013691","journal-title":"JAMA"},{"issue":"11","key":"3090_CR6","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1377\/hlthaff.2017.0832","volume":"36","author":"BR Bloem","year":"2017","unstructured":"Bloem BR, Rompen L, Vries NM, Klink A, Munneke M, Jeurissen P (2017) ParkinsonNet: a low-cost health care innovation with a systems approach from the Netherlands. Health Aff (Millwood) 36(11):1987\u20131996. https:\/\/doi.org\/10.1377\/hlthaff.2017.0832","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"3090_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10654-022-00878-1","volume":"37","author":"CC Bruck","year":"2022","unstructured":"Bruck CC, Wolters FJ, Ikram MA, de Kok I (2022) Projected prevalence and incidence of dementia accounting for secular trends and birth cohort effects: a population-based microsimulation study. Eur J Epidemiol 37(8):807\u2013814. https:\/\/doi.org\/10.1007\/s10654-022-00878-1","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"3090_CR8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12967-020-02223-0","volume":"18","author":"I Castilla-Cort\u00e1zar","year":"2020","unstructured":"Castilla-Cort\u00e1zar I, Aguirre GA, Femat-Rold\u00e1n G, Mart\u00edn-Estal I, Espinosa L (2020) Is insulin-like growth factor-1 involved in Parkinson\u2019s disease development? J Transl Med 18(1):70. https:\/\/doi.org\/10.1186\/s12967-020-02223-0","journal-title":"J Transl Med"},{"issue":"6","key":"3090_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/mds.28551","volume":"36","author":"H Chohan","year":"2021","unstructured":"Chohan H, Senkevich K, Patel RK, Bestwick JP, Jacobs BM, Bandres Ciga S, Gan-Or Z, Noyce AJ (2021) Type 2 diabetes as a determinant of Parkinson\u2019s disease risk and progression. Mov Disord 36(6):1420\u20131429. https:\/\/doi.org\/10.1002\/mds.28551","journal-title":"Mov Disord"},{"issue":"1","key":"3090_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s00018-024-05262-8","volume":"81","author":"L Clausen","year":"2024","unstructured":"Clausen L, Okarmus J, Voutsinos V, Meyer M, Lindorff-Larsen K, Hartmann-Petersen R (2024) PRKN-linked familial Parkinson\u2019s disease: cellular and molecular mechanisms of disease-linked variants. Cell Mol Life Sci 81(1):223. https:\/\/doi.org\/10.1007\/s00018-024-05262-8","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"3090_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/mds.29329","volume":"38","author":"L Concha-Marambio","year":"2023","unstructured":"Concha-Marambio L, Weber S, Farris CM, Dakna M, Lang E, Wicke T, Ma Y, Starke M, Ebentheuer J, Sixel-Doring F, Muntean ML, Schade S, Trenkwalder C, Soto C, Mollenhauer B (2023) Accurate detection of alpha-Synuclein seeds in cerebrospinal fluid from isolated rapid eye movement sleep behavior disorder and patients with Parkinson\u2019s disease in the DeNovo Parkinson (DeNoPa) cohort. Mov Disord 38(4):567\u2013578. https:\/\/doi.org\/10.1002\/mds.29329","journal-title":"Mov Disord"},{"issue":"1","key":"3090_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01666-7","volume":"17","author":"JL Cummings","year":"2025","unstructured":"Cummings JL, Atri A, Feldman HH, Hansson O, Sano M, Knop FK, Johannsen P, Leon T, Scheltens P (2025) Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):14. https:\/\/doi.org\/10.1186\/s13195-024-01666-7","journal-title":"Alzheimers Res Ther"},{"issue":"6","key":"3090_CR13","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","volume":"5","author":"LM de Lau","year":"2006","unstructured":"de Lau LM, Breteler MM (2006) Epidemiology of Parkinson\u2019s disease. Lancet Neurol 5(6):525\u2013535. https:\/\/doi.org\/10.1016\/S1474-4422(06)70471-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"3090_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"75","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR (2018) The Parkinson pandemic-a call to action. JAMA Neurol 75(1):9\u201310. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3299","journal-title":"JAMA Neurol"},{"issue":"12","key":"3090_CR15","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, Kivipelto M, Jessen F, Hanseeuw B, Boada M, Barkhof F, Nordberg A, Froelich L, Waldemar G, Frederiksen KS, Padovani A, Planche V, Rowe C, Bejanin A, Frisoni GB (2024) Alzheimer disease as a clinical-biological construct-an international working group recommendation. JAMA Neurol 81(12):1304\u20131311. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3770","journal-title":"JAMA Neurol"},{"key":"3090_CR16","unstructured":"European Observatory on Health Systems and Policies. (2024). Luxembourg: Health system review. Health Systems in Transition, 26(1). World Health Organization, Regional Office for Europe."},{"issue":"1","key":"3090_CR17","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/1877718X241306132","volume":"15","author":"A Fink","year":"2025","unstructured":"Fink A, Pavlou MAS, Roomp K, Schneider JG (2025) Declining trends in the incidence of Parkinson\u2019s disease: a cohort study in Germany. J Parkinsons Dis 15(1):182\u2013188. https:\/\/doi.org\/10.1177\/1877718X241306132","journal-title":"J Parkinsons Dis"},{"issue":"5","key":"3090_CR18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209699","volume":"103","author":"J Gallagher","year":"2024","unstructured":"Gallagher J, Gochanour C, Caspell-Garcia C, Dobkin RD, Aarsland D, Alcalay RN, Barrett MJ, Chahine L, Chen-Plotkin AS, Coffey CS, Dahodwala N, Eberling JL, Espay AJ, Leverenz JB, Litvan I, Mamikonyan E, Morley J, Richard IH, Rosenthal L, Parkinson\u2019s Progression Markers, I. (2024) Long-term dementia risk in Parkinson disease. Neurology 103(5):e209699. https:\/\/doi.org\/10.1212\/WNL.0000000000209699","journal-title":"Neurology"},{"issue":"6","key":"3090_CR19","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1532-5415.2009.02267.x","volume":"57","author":"S Gao","year":"2009","unstructured":"Gao S, Jin Y, Unverzagt FW, Liang C, Hall KS, Ma F, Murrell JR, Cheng Y, Matesan J, Bian J, Li P, Hendrie HC (2009) Hypertension and cognitive decline in rural elderly Chinese. J Am Geriatr Soc 57(6):1051\u20131057. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02267.x","journal-title":"J Am Geriatr Soc"},{"issue":"1","key":"3090_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00700-7","volume":"10","author":"T Geng","year":"2024","unstructured":"Geng T, Li Y, Peng Y, Chen X, Xu X, Wang J, Sun L, Gao X (2024) Social isolation and the risk of Parkinson disease in the UK biobank study. NPJ Parkinsons Dis 10(1):79. https:\/\/doi.org\/10.1038\/s41531-024-00700-7","journal-title":"NPJ Parkinsons Dis"},{"issue":"10","key":"3090_CR21","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1002\/mds.29918","volume":"39","author":"LL Gibson","year":"2024","unstructured":"Gibson LL, Weintraub D, Lemmen R, Perera G, Chaudhuri KR, Svenningsson P, Aarsland D (2024) Risk of dementia in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 39(10):1697\u20131709. https:\/\/doi.org\/10.1002\/mds.29918","journal-title":"Mov Disord"},{"issue":"6","key":"3090_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1474-4422(24)00121-2","volume":"23","author":"EK Gustavsson","year":"2024","unstructured":"Gustavsson EK, Follett J, Trinh J, Barodia SK, Real R, Liu Z, Grant-Peters M, Fox JD, Appel-Cresswell S, Stoessl AJ, Rajput A, Rajput AH, Auer R, Tilney R, Sturm M, Haack TB, Lesage S, Tesson C, Brice A, Farrer MJ (2024) RAB32 Ser71Arg in autosomal dominant Parkinson\u2019s disease: linkage, association, and functional analyses. Lancet Neurol 23(6):603\u2013614. https:\/\/doi.org\/10.1016\/S1474-4422(24)00121-2","journal-title":"Lancet Neurol"},{"issue":"1","key":"3090_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12889-019-7010-z","volume":"19","author":"I Heger","year":"2019","unstructured":"Heger I, Deckers K, van Boxtel M, de Vugt M, Hajema K, Verhey F, Kohler S (2019) Dementia awareness and risk perception in middle-aged and older individuals: baseline results of the MijnBreincoach survey on the association between lifestyle and brain health. BMC Public Health 19(1):678. https:\/\/doi.org\/10.1186\/s12889-019-7010-z","journal-title":"BMC Public Health"},{"issue":"1","key":"3090_CR24","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/gps.4284","volume":"31","author":"JV Hindle","year":"2016","unstructured":"Hindle JV, Hurt CS, Burn DJ, Brown RG, Samuel M, Wilson KC, Clare L (2016) The effects of cognitive reserve and lifestyle on cognition and dementia in Parkinson\u2019s disease\u2013a longitudinal cohort study. Int J Geriatr Psychiatry 31(1):13\u201323. https:\/\/doi.org\/10.1002\/gps.4284","journal-title":"Int J Geriatr Psychiatry"},{"key":"3090_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2018.00326","volume":"10","author":"G Hipp","year":"2018","unstructured":"Hipp G, Vaillant M, Diederich NJ, Roomp K, Satagopam VP, Banda P, Sandt E, Mommaerts K, Schmitz SK, Longhino L, Schweicher A, Hanff AM, Nicolai B, Kolber P, Reiter D, Pavelka L, Binck S, Pauly C, Geffers L, Kruger R (2018) The Luxembourg Parkinson\u2019s study: a comprehensive approach for stratification and early diagnosis. Front Aging Neurosci 10:326. https:\/\/doi.org\/10.3389\/fnagi.2018.00326","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"3090_CR26","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D, Klein C, Outeiro TF, Poewe W, Postuma R, Stoessl AJ, Lang AE (2024) A biological classification of Parkinson\u2019s disease: the SynNeurGe research diagnostic criteria. Lancet Neurol 23(2):191\u2013204. https:\/\/doi.org\/10.1016\/S1474-4422(23)00404-0","journal-title":"Lancet Neurol"},{"issue":"1","key":"3090_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12929-024-01090-x","volume":"31","author":"CT Hong","year":"2024","unstructured":"Hong CT, Chen JH, Hu CJ (2024) Role of glucagon-like peptide-1 receptor agonists in Alzheimer\u2019s disease and Parkinson\u2019s disease. J Biomed Sci 31(1):102. https:\/\/doi.org\/10.1186\/s12929-024-01090-x","journal-title":"J Biomed Sci"},{"issue":"s2","key":"3090_CR28","doi-asserted-by":"publisher","first-page":"S297","DOI":"10.3233\/JPD-230419","volume":"14","author":"M Hu","year":"2024","unstructured":"Hu M, Skjaerbaek C, Borghammer P (2024) Approaches to early Parkinson\u2019s disease subtyping. J Parkinsons Dis 14(s2):S297\u2013S306. https:\/\/doi.org\/10.3233\/JPD-230419","journal-title":"J Parkinsons Dis"},{"key":"3090_CR29","unstructured":"International, A. s. D. (2024). World Alzheimer Report 2024: Global changes in attitudes to dementia."},{"issue":"4","key":"3090_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr.","year":"2018","unstructured":"Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Contributors (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers & Dementia 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers & Dementia"},{"issue":"8","key":"3090_CR31","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr.","year":"2024","unstructured":"Jack CR Jr., Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, Hansson O, Ho C, Jagust W, McDade E, Molinuevo JL, Okonkwo OC, Pani L, Rafii MS, Scheltens P, Siemers E, Snyder HM, Sperling R, Teunissen CE, Carrillo MC (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"8","key":"3090_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1056\/NEJMoa2310168","volume":"390","author":"J Jia","year":"2024","unstructured":"Jia J, Ning Y, Chen M, Wang S, Yang H, Li F, Ding J, Li Y, Zhao B, Lyu J, Yang S, Yan X, Wang Y, Qin W, Wang Q, Li Y, Zhang J, Liang F, Liao Z, Wang S (2024) Biomarker changes during 20 years preceding Alzheimer\u2019s disease. N Engl J Med 390(8):712\u2013722. https:\/\/doi.org\/10.1056\/NEJMoa2310168","journal-title":"N Engl J Med"},{"issue":"2","key":"3090_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/ana.26291","volume":"91","author":"ME Johansson","year":"2022","unstructured":"Johansson ME, Cameron IGM, Van der Kolk NM, de Vries NM, Klimars E, Toni I, Bloem BR, Helmich RC (2022) Aerobic exercise alters brain function and structure in Parkinson\u2019s disease: a randomized controlled trial. Ann Neurol 91(2):203\u2013216. https:\/\/doi.org\/10.1002\/ana.26291","journal-title":"Ann Neurol"},{"issue":"6","key":"3090_CR34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s42451-025-00795-z","volume":"8","author":"E Kalbe","year":"2025","unstructured":"Kalbe E, Warnecke T, Eggers C, Ophey A, Folkerts AK (2025a) Kognitive St\u00f6rungen bei der Parkinson-Krankheit: Zeit f\u00fcr Pr\u00e4vention? Dgneurologie 8(6):497\u2013503. https:\/\/doi.org\/10.1007\/s42451-025-00795-z","journal-title":"Dgneurologie"},{"key":"3090_CR35","doi-asserted-by":"publisher","DOI":"10.1177\/1877718X251365769","author":"E Kalbe","year":"2025","unstructured":"Kalbe E, Warnecke T, Eggers C, Ophey A, Folkerts AK (2025b) Prevention of cognitive impairment and dementia in people with Parkinson\u2019s disease: a call-to-action. J Parkinsons Dis. https:\/\/doi.org\/10.1177\/1877718X251365769","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"3090_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1186\/s12967-025-06354-0","volume":"23","author":"M Karami","year":"2025","unstructured":"Karami M, Sanaye PM, Ghorbani A, Amirian R, Goleij P, Babamohamadi M, Izadi Z (2025) Recent advances in targeting LRRK2 for Parkinson\u2019s disease treatment. J Transl Med 23(1):754. https:\/\/doi.org\/10.1186\/s12967-025-06354-0","journal-title":"J Transl Med"},{"issue":"3","key":"3090_CR37","doi-asserted-by":"publisher","first-page":"289","DOI":"10.18999\/nagjms.80.3.289","volume":"80","author":"M Katsuno","year":"2018","unstructured":"Katsuno M, Sahashi K, Iguchi Y, Hashizume A (2018) Preclinical progression of neurodegenerative diseases. Nagoya J Med Sci 80(3):289\u2013298. https:\/\/doi.org\/10.18999\/nagjms.80.3.289","journal-title":"Nagoya J Med Sci"},{"issue":"7","key":"3090_CR38","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/alz.12123","volume":"16","author":"M Kivipelto","year":"2020","unstructured":"Kivipelto M, Mangialasche F, Snyder HM, Allegri R, Andrieu S, Arai H, Baker L, Belleville S, Brodaty H, Brucki SM, Calandri I, Caramelli P, Chen C, Chertkow H, Chew E, Choi SH, Chowdhary N, Crivelli L, Torre R, Carrillo MC (2020) World-Wide FINGERS Network: a global approach to risk reduction and prevention of dementia. Alzheimers Dement 16(7):1078\u20131094. https:\/\/doi.org\/10.1002\/alz.12123","journal-title":"Alzheimers Dement"},{"issue":"2","key":"3090_CR39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/ng0298-106","volume":"18","author":"R Kr\u00fcger","year":"1998","unstructured":"Kr\u00fcger R, Kuhn W, M\u00fcller T, Woitalla D, Graeber M, K\u00f6sel S, Przuntek H, Epplen JT, Sch\u00f6ls L, Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson\u2019s disease. Nat Genet 18(2):106\u2013108. https:\/\/doi.org\/10.1038\/ng0298-106. (PMID: 9462735)","journal-title":"Nat Genet"},{"key":"3090_CR40","doi-asserted-by":"publisher","first-page":"1282174","DOI":"10.3389\/fnagi.2023.1282174","volume":"15","author":"Landoulsi, Z., Pachchek, S., Bobbili, D. R., Pavelka, L., May, P., Kruger, R., & Consortium, N.-P","year":"2023","unstructured":"Landoulsi, Z., Pachchek, S., Bobbili, D. R., Pavelka, L., May, P., Kruger, R., & Consortium, N.-P (2023) Genetic landscape of Parkinson\u2019s disease and related diseases in Luxembourg. Front Aging Neurosci 15:1282174. https:\/\/doi.org\/10.3389\/fnagi.2023.1282174","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"3090_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41746-024-01135-3","volume":"7","author":"F Lin","year":"2024","unstructured":"Lin F, Lin Y, Chen L, Huang T, Lin T, He J, Lu X, Chen X, Wang Y, Ye Q, Cai G (2024) Association of physical activity pattern and risk of Parkinson\u2019s disease. NPJ Digit Med 7(1):137. https:\/\/doi.org\/10.1038\/s41746-024-01135-3","journal-title":"NPJ Digit Med"},{"issue":"10452","key":"3090_CR43","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, Ames D, Banerjee S, Burns A, Brayne C, Fox NC, Ferri CP, Gitlin LN, Howard R, Kales HC, Kivimaki M, Larson EB, Nakasujja N, Rockwood K, Mukadam N (2024) Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet 404(10452):572\u2013628. https:\/\/doi.org\/10.1016\/S0140-6736(24)01296-0","journal-title":"Lancet"},{"issue":"2","key":"3090_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/mdc3.14264","volume":"12","author":"Mahlknecht, P., Leiter, S., Horlings, C., Schwarzov\u00e1, K., Egner, I., Stockner, H., Marini, K., Theyer, C., Zamarian, L., Djamshidian, A., Seppi, K., Farfan, F., Garrido, A., Ghosh, S., Kr\u00fcger, R., McIntyre, D., Mollenhauer, B., Noyce, A., Pauly, C., Pilco-Janeta, D. F., \u2026 HeBA Consortium","year":"2025","unstructured":"Mahlknecht, P., Leiter, S., Horlings, C., Schwarzov\u00e1, K., Egner, I., Stockner, H., Marini, K., Theyer, C., Zamarian, L., Djamshidian, A., Seppi, K., Farfan, F., Garrido, A., Ghosh, S., Kr\u00fcger, R., McIntyre, D., Mollenhauer, B., Noyce, A., Pauly, C., Pilco-Janeta, D. F., \u2026 HeBA Consortium (2025) Preferences regarding disclosure of risk for Parkinson\u2019s disease in a population-based study. Mov Disord Clin Pract 12(2):203\u2013209. https:\/\/doi.org\/10.1002\/mdc3.14264","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"3090_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ene.15698","volume":"30","author":"MI Maraki","year":"2023","unstructured":"Maraki MI, Yannakoulia M, Xiromerisiou G, Stefanis L, Charisis S, Giagkou N, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, Scarmeas N, Stamelou M (2023) Mediterranean diet is associated with a lower probability of prodromal Parkinson\u2019s disease and risk for Parkinson\u2019s disease\/dementia with Lewy bodies: a longitudinal study. Eur J Neurol 30(4):934\u2013942. https:\/\/doi.org\/10.1111\/ene.15698","journal-title":"Eur J Neurol"},{"issue":"13","key":"3090_CR46","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"Meissner, W. G., Remy, P., Giordana, C., Maltete, D., Derkinderen, P., Houeto, J. L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carriere, N., Catala, H., Colin, O., Corvol, J. C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M.,\u2026Group, L. S","year":"2024","unstructured":"Meissner, W. G., Remy, P., Giordana, C., Maltete, D., Derkinderen, P., Houeto, J. L., Anheim, M., Benatru, I., Boraud, T., Brefel-Courbon, C., Carriere, N., Catala, H., Colin, O., Corvol, J. C., Damier, P., Dellapina, E., Devos, D., Drapier, S., Fabbri, M.,\u2026Group, L. S (2024) Trial of Lixisenatide in early Parkinson\u2019s disease. N Engl J Med 390(13):1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323","journal-title":"N Engl J Med"},{"key":"3090_CR47","unstructured":"MijnBreincoach. (n.d.). MijnBreincoach. MijnBreincoach. Retrieved 30 October from https:\/\/www.mijnbreincoach.eu\/"},{"key":"3090_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105950","volume":"120","author":"CM Mostert","year":"2025","unstructured":"Mostert CM, Udeh-Momoh C, Winkler AS, McLaughlin C, Eyre H, Salama M, Ranchod K, Trepel D, Vradenburg G, Hynes W, Fieggen G, Ali S, Mekkaoui NEL, Landay A, Bobrow K, Muyela L, Atkins K, Chadha AS, Marongiu R, Ibanez A (2025) Broadening dementia risk models: building on the 2024 Lancet Commission report for a more inclusive global framework. EBioMedicine 120:105950. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105950","journal-title":"EBioMedicine"},{"issue":"7","key":"3090_CR49","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2468-2667(24)00120-8","volume":"9","author":"N Mukadam","year":"2024","unstructured":"Mukadam N, Wolters FJ, Walsh S, Wallace L, Brayne C, Matthews FE, Sacuiu S, Skoog I, Seshadri S, Beiser A, Ghosh S, Livingston G (2024) Changes in prevalence and incidence of dementia and risk factors for dementia: an analysis from cohort studies. Lancet Public Health 9(7):e443\u2013e460. https:\/\/doi.org\/10.1016\/S2468-2667(24)00120-8","journal-title":"Lancet Public Health"},{"issue":"8","key":"3090_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1212\/01.wnl.0000180516.69442.95","volume":"65","author":"D Muslimovic","year":"2005","unstructured":"Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65(8):1239\u20131245. https:\/\/doi.org\/10.1212\/01.wnl.0000180516.69442.95","journal-title":"Neurology"},{"issue":"Pt 7","key":"3090_CR51","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann J, Bras J, Deas E, O\u2019Sullivan SS, Parkkinen L, Lachmann RH, Li A, Holton J, Guerreiro R, Paudel R, Segarane B, Singleton A, Lees A, Hardy J, Houlden H, Revesz T, Wood NW (2009) Glucocerebrosidase mutations in clinical and pathologically proven Parkinson\u2019s disease. Brain 132(Pt 7):1783\u20131794. https:\/\/doi.org\/10.1093\/brain\/awp044","journal-title":"Brain"},{"issue":"9984","key":"3090_CR52","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1016\/S0140-6736(15)60461-5","volume":"385","author":"T Ngandu","year":"2015","unstructured":"Ngandu T, Lehtisalo J, Solomon A, Levalahti E, Ahtiluoto S, Antikainen R, Backman L, Hanninen T, Jula A, Laatikainen T, Lindstrom J, Mangialasche F, Paajanen T, Pajala S, Peltonen M, Rauramaa R, Stigsdotter-Neely A, Strandberg T, Tuomilehto J, Kivipelto M (2015) A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet 385(9984):2255\u20132263. https:\/\/doi.org\/10.1016\/S0140-6736(15)60461-5","journal-title":"Lancet"},{"key":"3090_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107257","volume":"132","author":"T Nikolcheva","year":"2025","unstructured":"Nikolcheva T, Pagano G, Pross N, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Seppi K, Monnet A, Shariati N, Ricci B, Rutten-Jacobs L, Respondek G, Kustermann T, Taylor KI, Trundell D, Fontoura P, Doody R (2025) A phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson\u2019s disease (PADOVA): rationale, design, and baseline data. Parkinsonism Relat Disord 132:107257. https:\/\/doi.org\/10.1016\/j.parkreldis.2024.107257","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"3090_CR54","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol 13(8):788\u2013794. https:\/\/doi.org\/10.1016\/S1474-4422(14)70136-X","journal-title":"Lancet Neurol"},{"issue":"6","key":"3090_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1600-0404.2011.01491.x","volume":"124","author":"A Ogunniyi","year":"2011","unstructured":"Ogunniyi A, Lane KA, Baiyewu O, Gao S, Gureje O, Unverzagt FW, Murrell JR, Smith-Gamble V, Hall KS, Hendrie HC (2011) Hypertension and incident dementia in community-dwelling elderly Yoruba Nigerians. Acta Neurol Scand 124(6):396\u2013402. https:\/\/doi.org\/10.1111\/j.1600-0404.2011.01491.x","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"3090_CR56","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1038\/s41591-023-02358-9","volume":"29","author":"A Okuzumi","year":"2023","unstructured":"Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gerardy JJ, Mittelbronn M, Kruger R, Hattori N (2023) Propagative alpha-synuclein seeds as serum biomarkers for synucleinopathies. Nat Med 29(6):1448\u20131455. https:\/\/doi.org\/10.1038\/s41591-023-02358-9","journal-title":"Nat Med"},{"issue":"1","key":"3090_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41531-021-00203-9","volume":"7","author":"LMA Oliveira","year":"2021","unstructured":"Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF (2021) Alpha-synuclein research: defining strategic moves in the battle against Parkinson\u2019s disease. NPJ Parkinsons Dis 7(1):65","journal-title":"NPJ Parkinsons Dis"},{"issue":"1","key":"3090_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41531-025-01161-2","volume":"11","author":"A Ophey","year":"2025","unstructured":"Ophey A, Rottgen S, Doppler CEJ, Scharfenberg D, Kufer K, Farrher E, Fink GR, Sommerauer M, Kalbe E (2025) Subjective cognitive decline inindividuals with isolated REM sleep behavior disorder. NPJ Parkinsons Dis 11(1):287. https:\/\/doi.org\/10.1038\/s41531-025-01161-2","journal-title":"NPJ Parkinsons Dis"},{"issue":"7","key":"3090_CR59","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S1474-4422(25)00157-7","volume":"24","author":"CD Orru","year":"2025","unstructured":"Orru CD, Vaughan DP, Vijiaratnam N, Real R, Martinez-Carrasco A, Fumi R, Jensen MT, Hodgson M, Girges C, Gil-Martinez AL, Stafford EJ, Wu L, Lerche S, Wurster I, Groveman BR, Hughson AG, Ansorge O, Quaegebeur A, Allinson KSJ, Jabbari E (2025) Diagnostic and prognostic value of \u03b1-synuclein seed amplification assay kinetic measures in Parkinson\u2019s disease: a longitudinal cohort study. Lancet Neurol 24(7):580\u2013590. https:\/\/doi.org\/10.1016\/S1474-4422(25)00157-7","journal-title":"Lancet Neurol"},{"issue":"1","key":"3090_CR60","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41531-023-00595-w","volume":"9","author":"Pachchek, S., Landoulsi, Z., Pavelka, L., Schulte, C., Buena-Atienza, E., Gross, C., Hauser, A. K., Reddy Bobbili, D., Casadei, N., May, P., Kruger, R., & Consortium, N.-P","year":"2023","unstructured":"Pachchek, S., Landoulsi, Z., Pavelka, L., Schulte, C., Buena-Atienza, E., Gross, C., Hauser, A. K., Reddy Bobbili, D., Casadei, N., May, P., Kruger, R., & Consortium, N.-P (2023) Accurate long-read sequencing identified GBA1 as major risk factor in the Luxembourgish Parkinson\u2019s study. NPJ Parkinsons Dis 9(1):156. https:\/\/doi.org\/10.1038\/s41531-023-00595-w","journal-title":"NPJ Parkinsons Dis"},{"issue":"4","key":"3090_CR61","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"Pagano, G., Taylor, K. I., Anzures Cabrera, J., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Brockmann, K., Svoboda, H., Trundell, D., Monnet, A., Doody, R., Fontoura, P., Kerchner, G. A., Brundin, P., Nikolcheva, T., Bonni, A., Investigators, P., & Prasinezumab Study, G","year":"2024","unstructured":"Pagano, G., Taylor, K. I., Anzures Cabrera, J., Simuni, T., Marek, K., Postuma, R. B., Pavese, N., Stocchi, F., Brockmann, K., Svoboda, H., Trundell, D., Monnet, A., Doody, R., Fontoura, P., Kerchner, G. A., Brundin, P., Nikolcheva, T., Bonni, A., Investigators, P., & Prasinezumab Study, G (2024) Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med 30(4):1096\u20131103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y","journal-title":"Nat Med"},{"issue":"3","key":"3090_CR62","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3988\/jcn.2015.11.3.212","volume":"11","author":"T Paillard","year":"2015","unstructured":"Paillard T, Rolland Y, de Souto Barreto P (2015) Protective effects of physical exercise in Alzheimer\u2019s disease and Parkinson\u2019s disease: a narrative review. J Clin Neurol 11(3):212\u2013219. https:\/\/doi.org\/10.3988\/jcn.2015.11.3.212","journal-title":"J Clin Neurol"},{"key":"3090_CR63","doi-asserted-by":"publisher","first-page":"1330321","DOI":"10.3389\/fneur.2023.1330321","volume":"14","author":"Pavelka, L., Rawal, R., Ghosh, S., Pauly, C., Pauly, L., Hanff, A. M., Kolber, P. L., Jonsdottir, S. R., McIntyre, D., Azaiz, K., Thiry, E., Vilasboas, L., Soboleva, E., Giraitis, M., Tsurkalenko, O., Sapienza, S., Diederich, N., Klucken, J., Glaab, E.,\u2026Consortium, N.-P","year":"2023","unstructured":"Pavelka, L., Rawal, R., Ghosh, S., Pauly, C., Pauly, L., Hanff, A. M., Kolber, P. L., Jonsdottir, S. R., McIntyre, D., Azaiz, K., Thiry, E., Vilasboas, L., Soboleva, E., Giraitis, M., Tsurkalenko, O., Sapienza, S., Diederich, N., Klucken, J., Glaab, E.,\u2026Consortium, N.-P (2023) Luxembourg Parkinson\u2019s study -comprehensive baseline analysis of Parkinson\u2019s disease and atypical parkinsonism. Front Neurol 14:1330321. https:\/\/doi.org\/10.3389\/fneur.2023.1330321","journal-title":"Front Neurol"},{"key":"3090_CR64","unstructured":"PDP. pdp Braincoach. PDP. Retrieved 30 October from https:\/\/pdp.lu\/en\/braincoach\/"},{"key":"3090_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00660-y","volume":"10","author":"N Pena","year":"2024","unstructured":"Pena N, Richbourg T, Gonzalez-Hunt CP, Qi R, Wren P, Barlow C, Shanks NF, Carlisle HJ, Sanders LH (2024) G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage. Npj Parkinson\u2019s Disease 10:49. https:\/\/doi.org\/10.1038\/s41531-024-00660-y","journal-title":"Npj Parkinson's Disease"},{"issue":"1","key":"3090_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00779-y","volume":"10","author":"GM Pereira","year":"2024","unstructured":"Pereira GM, Teixeira-Dos-Santos D, Soares NM, Marconi GA, Friedrich DC, Saffie Awad P, Santos-Lobato BL, Brandao PRP, Noyce AJ, Marras C, Mata IF, Rieder CRM, Schuh AFS (2024) A systematic review and meta-analysis of the prevalence of Parkinson\u2019s disease in lower to upper-middle-income countries. NPJ Parkinsons Dis 10(1):181. https:\/\/doi.org\/10.1038\/s41531-024-00779-y","journal-title":"NPJ Parkinsons Dis"},{"key":"3090_CR67","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"issue":"5321","key":"3090_CR68","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science 276(5321):2045\u20132047. https:\/\/doi.org\/10.1126\/science.276.5321.2045","journal-title":"Science"},{"key":"3090_CR69","doi-asserted-by":"publisher","DOI":"10.1101\/2024.09.17.613365","author":"ND Raig","year":"2025","unstructured":"Raig ND, Surridge KJ, Sanz-Murillo M, Dederer V, Kramer A, Schwalm MP, Elson L, Chatterjee D, Mathea S, Hanke T, Leschziner AE, Reck-Peterson SL, Knapp S (2025) Type-II kinase inhibitors that target Parkinson\u2019s Disease-associated LRRK2. bioRxiv. https:\/\/doi.org\/10.1101\/2024.09.17.613365","journal-title":"bioRxiv"},{"issue":"1","key":"3090_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.14283\/jpad.2019.41","volume":"7","author":"A Rosenberg","year":"2020","unstructured":"Rosenberg A, Mangialasche F, Ngandu T, Solomon A, Kivipelto M (2020) Multidomain interventions to prevent cognitive impairment, Alzheimer\u2019s disease, and dementia: from FINGER to world-wide FINGERS. J Prev Alzheimers Dis 7(1):29\u201336. https:\/\/doi.org\/10.14283\/jpad.2019.41","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"3090_CR71","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s10654-014-9887-2","volume":"29","author":"K S\u00e4\u00e4ksjarvi","year":"2014","unstructured":"S\u00e4\u00e4ksjarvi K, Knekt P, Mannisto S, Lyytinen J, Jaaskelainen T, Kanerva N, Heliovaara M (2014) Reduced risk of Parkinson\u2019s disease associated with lower body mass index and heavy leisure-time physical activity. Eur J Epidemiol 29(4):285\u2013292. https:\/\/doi.org\/10.1007\/s10654-014-9887-2","journal-title":"Eur JEpidemiol"},{"issue":"Pt 3","key":"3090_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116600","volume":"230","author":"N Safreena","year":"2024","unstructured":"Safreena N, Nair IC, Chandra G (2024) Therapeutic potential of Parkin and its regulation in Parkinson\u2019s disease. Biochem Pharmacol 230(Pt 3):116600. https:\/\/doi.org\/10.1016\/j.bcp.2024.116600","journal-title":"Biochem Pharmacol"},{"key":"3090_CR73","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.parkreldis.2021.06.002","volume":"89","author":"A Sanchez-Gomez","year":"2021","unstructured":"Sanchez-Gomez A, Diaz Y, Duarte-Salles T, Compta Y, Marti MJ (2021) Prediabetes, type 2 diabetes mellitus and risk of Parkinson\u2019s disease: A population-based cohort study. Parkinsonism Relat Disord 89:22\u201327. https:\/\/doi.org\/10.1016\/j.parkreldis.2021.06.002","journal-title":"Parkinsonism Relat Disord"},{"issue":"6","key":"3090_CR74","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1504327","volume":"374","author":"CL Satizabal","year":"2016","unstructured":"Satizabal CL, Beiser AS, Chouraki V, Chene G, Dufouil C, Seshadri S (2016) Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med 374(6):523\u2013532. https:\/\/doi.org\/10.1056\/NEJMoa1504327","journal-title":"N Engl J Med"},{"issue":"1","key":"3090_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01008-w","volume":"11","author":"S Schade","year":"2025","unstructured":"Schade S, Ghosh S, Garrido A, Mahlknecht P, Marques TM, Horlings CGC, Jonsdottir SR, Lang E, Pauly C, Rege K, Schnell S, Starke M, Hakelberg H, Tolosa E, Trenkwalder C, Wicke T, Kruger R, Marti MJ, Mollenhauer B (2025) Identifying individuals at-risk of developing Parkinson\u2019s disease using a population-based recruitment strategy: the Healthy Brain Ageing Kassel Study. NPJ Parkinsons Dis 11(1):216. https:\/\/doi.org\/10.1038\/s41531-025-01008-w","journal-title":"NPJ Parkinsons Dis"},{"issue":"2","key":"3090_CR76","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3233\/JAD-230794","volume":"97","author":"VE Schr\u00f6der","year":"2024","unstructured":"Schr\u00f6der VE, Skrozic A, Erz D, Kaysen A, Fritz JV, Loureiro JM, McIntyre D, Pauly L, Kemp J, Schmitz SK, Wagner S, Reyes M, Soare R, Satagopam V, Vega C, Gawron P, Roomp K, Conde PM, Klucken J, Kruger R (2024) Programme Dementia Prevention (pdp): a nationwide program for personalized prevention in Luxembourg. J Alzheimers Dis 97(2):791\u2013804. https:\/\/doi.org\/10.3233\/JAD-230794","journal-title":"J Alzheimers Dis"},{"key":"3090_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2021.108822","volume":"202","author":"K Senkevich","year":"2022","unstructured":"Senkevich K, Rudakou U, Gan-Or Z (2022) New therapeutic approaches to Parkinson\u2019s disease targeting GBA, LRRK2 and Parkin. Neuropharmacology 202:108822.https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108822","journal-title":"Neuropharmacology"},{"issue":"1","key":"3090_CR78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/mds.29649","volume":"39","author":"M Siciliano","year":"2024","unstructured":"Siciliano M, Tessitore A, Morgante F, Goldman JG, Ricciardi L (2024) Subjective cognitive complaints in Parkinson\u2019s disease: a systematic review and meta-analysis. Mov Disord 39(1):17\u201328. https:\/\/doi.org\/10.1002\/mds.29649","journal-title":"Mov Disord"},{"issue":"5","key":"3090_CR79","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/S1474-4422(23)00109-6","volume":"22","author":"A Siderowf","year":"2023","unstructured":"Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D (2023) Assessment of heterogeneity among participants in the Parkinson\u2019s Progression Markers Initiative cohort using \u03b1-synuclein seed amplification: a cross-sectional study. Lancet Neurol 22(5):407\u2013417. https:\/\/doi.org\/10.1016\/S1474-4422(23)00109-6","journal-title":"Lancet Neurol"},{"issue":"12","key":"3090_CR80","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ng.487","volume":"41","author":"J Simon-Sanchez","year":"2009","unstructured":"Simon-Sanchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, Singleton AB (2009) Genome-wide association study reveals genetic risk underlying Parkinson\u2019s disease. Nat Genet 41(12):1308\u20131312. https:\/\/doi.org\/10.1038\/ng.487","journal-title":"Nat Genet"},{"issue":"6","key":"3090_CR81","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, Investigators T-A (2023) Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"2","key":"3090_CR82","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","volume":"23","author":"T Simuni","year":"2024","unstructured":"Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Marek K (2024) A biological definition of neuronal \u03b1-synuclein disease: towards an integrated staging system for research. Lancet Neurol 23(2):178\u2013190. https:\/\/doi.org\/10.1016\/S1474-4422(23)00405-2","journal-title":"LancetNeurol"},{"issue":"28","key":"3090_CR83","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha-synuclein in Lewy bodies. Nature 388(28):839\u2013840. https:\/\/doi.org\/10.1038\/42166","journal-title":"Nature"},{"issue":"6","key":"3090_CR84","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S2666-7568(24)00061-8","volume":"5","author":"BCM Stephan","year":"2024","unstructured":"Stephan BCM, Cochrane L, Kafadar AH, Brain J, Burton E, Myers B, Brayne C, Naheed A, Anstey KJ, Ashor AW, Siervo M (2024) Population attributable fractions of modifiable risk factors for dementia: a systematic review and meta-analysis. Lancet Healthy Longev 5(6):e406\u2013e421. https:\/\/doi.org\/10.1016\/S2666-7568(24)00061-8","journal-title":"Lancet Healthy Longev"},{"key":"3090_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C, Yin P, Bai R, Zhu J, Lam JST, Zhang J, Yan R, Zheng X, Wu J, Zhao D, Wang A, Zhou M, Feng T (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"issue":"11","key":"3090_CR86","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1001\/jamaneurol.2023.3382","volume":"80","author":"A Terracciano","year":"2023","unstructured":"Terracciano A, Luchetti M, Karakose S, Stephan Y, Sutin AR (2023) Loneliness and risk of Parkinson disease. JAMA Neurol 80(11):1138\u20131144. https:\/\/doi.org\/10.1001\/jamaneurol.2023.3382","journal-title":"JAMA Neurol"},{"issue":"1","key":"3090_CR87","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"10479","key":"3090_CR88","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","volume":"405","author":"N Vijiaratnam","year":"2025","unstructured":"Vijiaratnam N, Girges C, Auld G, McComish R, King A, Skene SS, Hibbert S, Wong A, Melander S, Gibson R, Matthews H, Dickson J, Carroll C, Patrick A, Inches J, Silverdale M, Blackledge B, Whiston J, Hu M, Foltynie T (2025) Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson\u2019s disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial. Lancet 405(10479):627\u2013636. https:\/\/doi.org\/10.1016\/S0140-6736(24)02808-3","journal-title":"Lancet"},{"issue":"5","key":"3090_CR89","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.14336\/AD.2024.1071","volume":"16","author":"S Wang","year":"2024","unstructured":"Wang S, Jiang Y, Yang A, Meng F, Zhang J (2024) The expanding burden of neurodegenerative diseases: an unmet medical and social need. Aging Dis 16(5):2937\u20132952. https:\/\/doi.org\/10.14336\/AD.2024.1071","journal-title":"Aging Dis"},{"issue":"6","key":"3090_CR90","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nrneurol.2017.63","volume":"13","author":"YT Wu","year":"2017","unstructured":"Wu YT, Beiser AS, Breteler MMB, Fratiglioni L, Helmer C, Hendrie HC, Honda H, Ikram MA, Langa KM, Lobo A, Matthews FE, Ohara T, Peres K, Qiu C, Seshadri S, Sjolund BM, Skoog I, Brayne C (2017) The changing prevalence and incidence of dementia over time - current evidence. Nat Rev Neurol 13(6):327\u2013339. https:\/\/doi.org\/10.1038\/nrneurol.2017.63","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"3090_CR91","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/brain\/awu323","volume":"138","author":"F Yang","year":"2015","unstructured":"Yang F, Trolle Lagerros Y, Bellocco R, Adami HO, Fang F, Pedersen NL, Wirdefeldt K (2015) Physical activity and risk of Parkinson\u2019s disease in the Swedish National March Cohort. Brain 138(2):269\u2013275. https:\/\/doi.org\/10.1093\/brain\/awu323","journal-title":"Brain"},{"issue":"4","key":"3090_CR92","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1212\/WNL.0000000000000066","volume":"82","author":"Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., Mollenhauer, B., Kruse, N., Hudson, G., Chinnery, P. F., O'Brien, J. T., Robbins, T. W., Wesnes, K., Brooks, D. J., Barker, R. A.,\u2026Group, I.-P. S","year":"2014","unstructured":"Yarnall, A. J., Breen, D. P., Duncan, G. W., Khoo, T. K., Coleman, S. Y., Firbank, M. J., Nombela, C., Winder-Rhodes, S., Evans, J. R., Rowe, J. B., Mollenhauer, B., Kruse, N., Hudson, G., Chinnery, P. F., O\u2019Brien, J. T., Robbins, T. W., Wesnes, K., Brooks, D. J., Barker, R. A.,\u2026Group, I.-P. S (2014) Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study. Neurology 82(4):308\u2013316. https:\/\/doi.org\/10.1212\/WNL.0000000000000066","journal-title":"Neurology"},{"issue":"6","key":"3090_CR93","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.14336\/AD.2022.0325","volume":"13","author":"H Yu","year":"2022","unstructured":"Yu H, Sun T, He X, Wang Z, Zhao K, An J, Wen L, Li JY, Li W, Feng J (2022) Association between Parkinson\u2019s disease and diabetes mellitus: from epidemiology, pathophysiology and prevention to treatment. Aging Dis 13(6):1591\u20131605. https:\/\/doi.org\/10.14336\/AD.2022.0325","journal-title":"Aging Dis"},{"issue":"1","key":"3090_CR94","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/mds.30039","volume":"40","author":"A Zagare","year":"2025","unstructured":"Zagare A, Hemedan A, Almeida C, Frangenberg D, Gomez-Giro G, Antony P, Halder R, Kruger R, Glaab E, Ostaszewski M, Arena G, Schwamborn JC (2025) Insulin resistance is a modifying factor for Parkinson\u2019s disease. Mov Disord 40(1):67\u201376. https:\/\/doi.org\/10.1002\/mds.30039","journal-title":"Mov Disord"},{"issue":"2","key":"3090_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnha.2024.100451","volume":"29","author":"J Zhao","year":"2025","unstructured":"Zhao J, Peng Y, Lin Z, Gong Y (2025) Association between Mediterranean diet adherence and Parkinson\u2019s disease: a systematic review and meta-analysis. J Nutr Health Aging 29(2):100451. https:\/\/doi.org\/10.1016\/j.jnha.2024.100451","journal-title":"J Nutr Health Aging"},{"issue":"4","key":"3090_CR96","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, Kachergus J, Hulihan M, Uitti RJ, Calne DB, Stoessl AJ, Pfeiffer RF, Patenge N, Carbajal IC, Vieregge P, Asmus F, M\u00fcller-Myhsok B, Dickson DW, Meitinger T, Strom TM, Wszolek ZK (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44(4):601\u2013607. https:\/\/doi.org\/10.1016\/j.neuron.2004.11.005","journal-title":"Neuron"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03090-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03090-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:20:06Z","timestamp":1769692806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03090-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,26]]},"references-count":96,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3090"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03090-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,26]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}